ED50

The Treg/Tresp ratio at which 50% inhibition of proliferation was achieved is defined as ED50 of suppression.

PLoS ONE Alerts: New Articles Joost Smolders et al. 2009

The use of the ED50 and LD50 doses to derive the TI may be misleading as to safety, depending on the slope of the dose-response curves for therapeutic and lethal effects.

Dose-response relationship 2008

For example, if the LD50 is 200 mg and the ED50 is 20 mg, the TI would be 10 (200/20).

Dose-response relationship 2008

As a result, we may more often see results expressed as ED50 or the effective dose (for whatever endpoint was selected for study) that leads to a 50% response of the test population.

Toxicology 2007

The ED50 for proliferation of the MC9/2 cell line is typically 0. 5-1.0 ng/mL.

FreshPatents.com: Notable Patent Applications - 07/22/2010 2010

In the case of a GalNAc-conjugated siRNA targeting transthyretin TTR, target gene silencing was achieved with an ED50 of approximately 5 mg/kg with a single subcutaneous injection.

Alnylam Presents New Data on Delivery of RNAi Therapeutics and Human Translation - Yahoo! Finance 2010

The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity.

FreshPatents.com: Notable Patent Applications - 07/22/2010 2010

The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio between LD50 and ED50.

FreshPatents.com: Notable Patent Applications - 07/22/2010 2010

Toxicity and therapeutic efficacy of the antibody compositions, administered alone or in combination with an immunosuppressive agent, can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population).

FreshPatents.com: Notable Patent Applications - 07/22/2010 2010

Overall patient recruitment is more biases dose-response curves to the right (i.e. tend ef fi cient. to overestimate the ED50) in comparison to a Clinical trialists should be wary of using rando - parallel-group study in the same patients with the mized, crossover designs when there are likely to same end points. be appreciable numbers of patients who are with - drawn before completing the study.

Recently Uploaded Slideshows martins0105 2009